Yolanda Ratchford Secures Bell Law Firm After Undiagnosed and Untreated Spinal Hematomas from Thrombectomy Surgery Led to Significant Neurological Deficits ATLANTA–(BUSINESS WIRE)–Lloyd Bell of Bell Law Firm today confirms the filing of a medical malpractice lawsuit on behalf of Yolanda Ratchford in DeKalb County against Emory University, Emory Healthcare, Inc., The Emory Clinic, Inc., AMN … [Read more…]

NEW YORK–(BUSINESS WIRE)–Establishment Labs Holdings Inc. (Nasdaq: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into agreements with four partners in Europe and a second partner chain in Japan for Mia Femtech™ (“Mia®”). “Our global rollout of Mia Femtech … [Read more…]

Program offers practical tools to equip parents to help their kids IRVINE, Calif.–(BUSINESS WIRE)–Tell My Story today announced the launch of its parent-centered school program to give them the tools to treat their kids’ mental health like they do their physical health. The program includes a documentary film, “What I Wish My Parents Knew,” and … [Read more…]

CareDx to Host Symposium Featuring the Latest Developments in Pediatric Transplant Care BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its gold-level sponsorship and participation at the 12th Congress of the … [Read more…]

LAWRENCE, Kan.–(BUSINESS WIRE)–#biotech—Endpoints News, the biopharma industry’s leading daily news publisher, announced today the appointment of Ryan McRae as Chief Revenue Officer (CRO). In this role, Mr. McRae will direct the company’s growing subscription and advertising businesses. He brings over a decade of media leadership experience to Endpoints, with previous senior revenue roles at The … [Read more…]

Following positive regulatory feedback, plan to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis; plan to initiate late-stage clinical trial activities in second half 2023, subject to regulatory alignment; expect to … [Read more…]

OXFORD, U.K.–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) Recent developments in the Company’s pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below. Exscientia will host a conference call today, March 23, at 12:30 p.m. GMT / 8:30 a.m. EDT. “2022 was marked by significant milestones for … [Read more…]

Milestone represents initiation of first-ever clinical trial using NR2B-negative allosteric modulator to treat GRIN-related disorders NEW YORK–(BUSINESS WIRE)–GRIN Therapeutics Inc., a leader in development of therapies to treat GRIN-related disorders, today announced that the first patient has been dosed in the Honeycomb Study, the Company’s Phase 1B clinical trial of radiprodil, an investigational NR2B-negative allosteric … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Artificial Corneal Implants Market Size, Share & Trends Analysis Report By Transplant Type (Hard Keratoprosthesis, Soft Keratoprosthesis), By Indication (Ocular Burns, Keratoconus), By Implant Type, By Region, And Segment Forecasts, 2023 – 2030” report has been added to ResearchAndMarkets.com’s offering. The global artificial corneal implants market size is expected to reach USD 118.3 … [Read more…]

First approval in the world for allogeneic cell therapy to treat corneal endothelial disease SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its novel … [Read more…]